Other single compounds
'bradykinin antagonists Icatibant, Noscapine
| 32337769 2020. (tt bradykinin) Noscapine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2 |
32359101 2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications
32526773 2020. Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection.
32359101 2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications
Almitrine
32505756 2020. Almitrine as a non-ventilatory strategy to improve intrapulmonary shunt in COVID-19 patients.
32505755 2020. Effect of almitrine bismesylate and inhaled nitric oxide on oxygenation in COVID-19 acute respiratory distress syndrome.
Nitric oxide
32526061 2020. Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection.
32387333 ä. Could nasal nitric oxide help to mitigate the severity of COVID-19?
32436029 2020. Nitric oxide inhalation as an interventional rescue therapy for COVID-19-induced acute respiratory distress syndrome.
PDE5 Inhibitors
32272196 2020. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology
32226695 ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)
H2S
32515982 2020. H2S as a potential defence against COVID-19?
Macrolide antibiotics
32249257 2020. Macrolide treatment for COVID-19: Will this be the way forward?
Azithromycin
32302411 2020. Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19
32534189 2020. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.
Teicoplanin
32179150 ä. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?
32454071 2020. Is teicoplanin a complementary treatment option for COVID-19? The question remains.
Doxycycline and other Tetracyclins
32339778 ä. Dapsone and Doxycycline could be potential treatment modalities for COVID-19
32314492 ä. Doxycycline, a widely used antibiotic in dermatology with a possible anti?inflammatory action against IL?6 in COVID?19 outbreak
32267566 2020. Therapeutic Potential for Tetracyclines in the Treatment of COVID-19
32533795 2020. Further aspects of doxycycline therapy in COVID-19.
32379302 2020. Cardiac safety and potential efficacy: two reasons for considering minocycline in place of azithromycin in COVID-19 management.
Metronidazole retarget
32259129 2020. Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen
Oleoylethanolamide
32327293 ä. Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19
Lauric acid nat. compd.
Nicotine nat. toxin
32353120 ä. Does Cigarette Smoking Protect Against SARS-CoV-2 Infection?
32242236 ä. COVID-19 and Smoking
| 32522666 2020. How nicotine can inhibit cytokine storm in the lungs and prevent or lessen the severity of COVID-19 infection? |
Dipyridamole retarget
32318327 ä. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19
CGRP calcitonin gene related peptide antagonists
32386433 2020. Could CGRP Antagonists Be Helpful in the Fight Against COVID-19?
Various Leads
- 9 retargeted: ternatin4, zotatifin, plitidepsin; haloperidol, melperone, clemastine, cloperastine, pb28, progesterone
- paper in nature
32251767 2020. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
32226695 ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)
BRD4 polycomb
32495654 2020. Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents.
Glycyrrhizin
32335281 ä. Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19
| 32077621 2020. Glycyrrhizic-Acid-Based Carbon Dots with High Antiviral Activity by Multisite Inhibition Mechanisms |
Ipecac
32245264 2020. Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses
Camostat mesilate serine proteinase inh
32347443 ä. Camostat mesilate therapy for COVID-19
32489508 2020. Simultaneous Treatment of COVID-19 With Serine Protease Inhibitor Camostat and/or Cathepsin L Inhibitor?
Nafamostat mesilate serine proteinase inh
32312781 2020. Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
32302456 2020. Potential of heparin and nafamostat combination therapy for COVID-19
32470602 2020. Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy.
Sodium pyruvate
32378817 2020. Inhaled Nebulized Sodium Pyruvate Use in COVID-19 Patients
alpha1 adrenergic antagonists
32352407 2020. Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor antagonists
32237190 ä. What does androgenetic alopecia have to do with COVID?19? An insight into a potential new therapy
Ciclesonide
32362440 ä. Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: Report of three cases
Melatonin
32217117 2020. COVID-19: Melatonin as a potential adjuvant treatment
32360622 2020. Comment on Melatonin as a potential adjuvant treatment for COVID-19
32334009 2020. Correspondence COVID-19: Melatonin as a potential adjuvant treatment
32347747 2020. Can melatonin reduce the severity of COVID-19 pandemic?
32314850 2020. Melatonin: Roles in influenza, Covid?19, and other viral infections
cannabinoids
32360437 ä. SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?
32273254 2020. Cannabidiol as prophylaxis for SARS-CoV-2 and COVID-19? Unfounded claims versus potential risks of medications during the pandemic
32519753 2020. The potential of cannabidiol in the COVID-19 pandemic: a hypothesis letter.
32380847 2020. Cannabis in the Time of Coronavirus Disease 2019: The Yin and Yang of the Endocannabinoid System in Immunocompetence
32467020 2020. A...: Cannabidiol as a potential anti-inflammatory treatment? .
32471272 2020. Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?
Oxytocin
32344303 ä. Oxytocin as a potential defence against Covid-19?
Resiniferatoxin
32292906 2020. The role of afferent pulmonary innervation in ARDS associated with COVID-19 and potential use of resiniferatoxin to improve prognosis: A review
TRPV1 target
C7147214 ä. Potential TRPV1 blockade to treat severe lung dysfunction in COVID-19 infection
32292907 2020. Standing out from the crowd in treating COVID-19 the title has been idioted from Potential TRPV1 blockade to treat severe lung dysfunction in COVID-19 infection.
Botox
32352081 ä. Perspectives for the use of therapeutic Botulinum toxin as a multifaceted candidate drug to attenuate COVID-19
PAK-1 target
32313880 ä. PAK1-blockers: Potential Therapeutics against COVID-19?
32348877 ä. Chemical evolution for taming the ?pathogenic kinase? PAK1
Endothelin antagonists
32361169 2020. Why not consider an endothelin receptor antagonist against SARS?CoV?2?
32360293 2020. Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?
Rho kinase inhibitors
32283223 2020. Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19)
Saikosaponins
32353743 2020. Purposing Saikosaponins for the treatment of COVID-19
32345124 2020. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets
Isotretinoin
32406143 2020. Could patients taking isotretinoin therapy be immune against SARS-CoV-2?
Fenretinide
32471278 2020. Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.
Dapsone
32344275 2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)
32339778 ä. Dapsone and Doxycycline could be potential treatment modalities for COVID-19
31931639 2020. Dapsone as treatment adjunct in ARDS
Apremilast
32449265 2020. Apremilast as a potential treatment option for COVID-19: no symptoms of infection in a psoriatic patient.
Olanzapine
32344275 2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)
ADAM17 as target
32291449 ä. ADAM17 inhibition may exert a protective effect on COVID-19
Dextrometorphan
Nitazoxaide
32360581 ä. Nitazoxanide/Azithromycin combination for COVID-19: A suggested new protocol for COVID-19 early management
tPA
| 32312290 2020. Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis |
| 31856018 2020. Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome? |
Plasminogen
32275753 ä. Plasminogen improves lung lesions and hypoxemia in patients with COVID-19
mTOR ihibitors
32313883 2020. Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review)
32334502 2020. The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment
32410266 2020. Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines.
Cyclophilin A inhibitors
32347055 2020. Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors
Alisporivir
| 32376613 2020. Inhibition of SARS-CoV-2 infection by the cyclophilin inhibitor Alisporivir (Debio 025) |
Cyclosporin A
32354685 ä. Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia
CD147
32307653 ä. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement
Bee venom
32360140 ä. Bee venom and SARS-CoV-2
Spironolactone
32297520 2020. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?
Imatinib
32376403 ä. Imatinib might constitute a treatment option for lung involvement in COVID-19
Luteolin
32339387 2020. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin
BTK Bruton Tyrosine Kinase ibrutiib
32302379 2020. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients
akt PKB
32519895 2020. Is targeting Akt a viable option to treat advanced-stage COVID-19 patients?
Abelson tyrosine kinase
32399097 2020. Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2.
Pannexin1 channels
32519892 2020. Consideration of Pannexin 1 channels in COVID-19 pathology and treatment.
NAD+
32534944 2020. Influence of NAD+ as an ageing-related immunomodulator on COVID 19 infection: A hypothesis.
Erythropoietin
32270515 2020. Does recombinant human Erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects?
32479920 2020. Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19.
32534130 2020. EPO in Patients With COVID-19: More Than an Erythropoietic Hormone.
Celastrol
32347602 2020. Should we try the antiinflammatory natural product, celastrol, for COVID-19?
1
32352871 2020. A Radiation Mitigator as a Potential Treatment for COVID-19
Ozone
C7203037 ä. (Vitamin-C; Ozone)Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19?
Thalidomide
C7186126 ä. Proposed use of thalidomide for the cytokine storm of COVID-19
stimulating the Platelets
| 32315397 2020. Promoting platelets is a therapeutic option to combat severe viral infection of the lung |
Thrombomodulin
23607598 2013. (x)Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome
Chlorpromazine
32387014 ä. Repositionnement de la chlorpromazine ... psychiatric patients could be protected from severe forms of COVID-19 by their psychotropic treatments
nAChR as target
32387130 ä. GTS-21, an alpha7nAChR agonist, suppressed the production of key inflammatory mediators by PBMCs that are elevated in COPD patients and associated with impaired lung function
Resolvins
32416413 2020. Covid-19 management with inflammation resolving mediators? Perspectives and potential
beta adrenergic antagonists
32388480 2020. Can beta-adrenergic blockers be used in the treatment of COVID-19?
Lithium
32435920 2020. Lithium's antiviral effects: a potential drug for CoViD-19 disease?
32534451 2020. Microdose lithium reduces cellular senescence in human astrocytes - a potential pharmacotherapy for COVID-19?
32518634 2020. Lithium and coronaviral infections. A scoping review.
32408073 2020. Lithium for the 2019 novel coronavirus
Resveratrol
32412158 2020. Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19.
32310688 2020. Biological plausibility for interactions between dietary fat, resveratrol, ACE2, and SARS-CoV illness severity.
Copper
32388476 2020. Is copper beneficial for COVID-19 patients?
Bismuth
32516203 2020. Temporal Improvement of a COVID-19-Positive Crohn's Disease Patient Treated With Bismuth Subsalicylate.
Anti Neoplastic agents
32398164 2020. Drug repurposing against COVID-19: focus on anticancer agents.
5-Fluorouracil 5-FU
32438240 2020. 5-Fluorouracil in combination with deoxyribonucleosides and deoxyribose as possible therapeutic options for the Coronavirus, COVID-19 infection
Gargling mouth rinses
32395245 2020. Hypertonic saline nasal irrigation and gargling should be considered as a treatment option for COVID-19.
PVP iodine
32520599 2020. Povidone-Iodine Use in Sinonasal and Oral Cavities: A Review of Safety in the COVID-19 Era.
Bromhexin
32458206 2020.... bromhexine as add-on therapy?
mabs
32534226 2020. Monoclonal antibody as a potential anti-COVID-19.
32514101 2020. First antibody against COVID-19 spike protein enters phase I.
tlr's
32391920 2020. Consider TLR5 for new therapeutic development against COVID-19.
p38 mapk
32422320 2020. p38 MAPK inhibition: A promising therapeutic approach for COVID-19.
lactoferrin
32529963 2020. Can lactoferrin boost human immunity against COVID-19?
Famotidine
32446698 2020. Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.
Proteasome inh
32443911 2020. Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2.
